Read by QxMD icon Read

Hematological Oncology

Laura Nanni, Alice Morigi, Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
No abstract text is available yet for this article.
January 13, 2019: Hematological Oncology
Maria K Angelopoulou, Theodoros P Vassilakopoulos, Eliana Konstantinou, George Boutsikas, John V Asimakopoulos, Evangelia-Faidra Triantafyllou, Kyriaki Petevi, Alexandros Kanellopoulos, Maria Moschogiannis, Gerassimos A Pangalis, Marina P Siakantaris, Kostas Konstantopoulos
We present two cases of splenic/primary bone marrow marginal zone lymphoma with secondary leptomeningeal CNS involvement, successfully treated with both systemic and intrathecal immunotherapy and we review the relevant literature. This complication is rare in this type of lymphomas at diagnosis or at relapse; as a rule, it seems to be the trigger for systemic disease. Leptomeningeal lymphomatous involvement in the context of systemic marginal zone lymphomas requires early recognition and it is associated with a favorable prognosis with non-intensive therapeutic measures, such as intrathecal immunotherapy...
December 28, 2018: Hematological Oncology
Roosa Prusila, Pekka Peroja, Esa Jantunen, Taina Turpeenniemi-Hujanen, Outi Kuittinen
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival (OS) is 60-70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and pre-exiting cardiac disease may prevent the use of doxorubicin. Age greater than 65 years is a significant risk factor for anthracycline-induced cardiotoxicity and therefore the use of R-CHOP is often withheld from elderly patients...
December 27, 2018: Hematological Oncology
Almudena Navarro-Bailón, Cristina Jiménez, Sara Alonso-Álvarez, Miguel Alcoceba, Verónica González-Calle, María Carmen Chillón, María García-Álvarez, Isabel Prieto, Alejandro Medina, Marcos González, María Dolores Caballero, Óscar Blanco, Luis Gonzaga Díaz, Ramón García-Sanz, María Eugenia Sarasquete
No abstract text is available yet for this article.
December 13, 2018: Hematological Oncology
Giulia Merlo, Emanuele Cozzani, Filippo Canale, Maurizio Miglino, Massimiliano Gambella, Martina Burlando, Aurora Parodi
In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. We divided the observed conditions in exanthematous, purpuric, vesicular-bullous, papulo-nodular, urticarial and eczematous manifestations. Moreover, all lesions were classified according to pathogenesis, in: (1) specific skin manifestations, caused by neoplastic skin infiltration; (2) immune-mediated manifestations, based on immunological mechanisms; (3) skin lesions due to immunodeficiency...
November 28, 2018: Hematological Oncology
Pashna N Munshi, Chaitra Ujjani
Recent advances in diffuse large B-cell lymphomas have included both identification of high-risk subtypes characterized by multiply relapsed and/or refractory disease as well as novel treatment in the form of cellular therapy. Chimeric antigen receptor (CAR)-T cell therapy is a recently developed approach to address the poor outcomes in this patient population. The CAR-T cell construct has evolved although several iterations as it transitioned from the lab to the clinic. Three major studies have evaluated the efficacy of CD19-directed CAR-T cell therapy in aggressive B-cell non-Hodgkin lymphoma; each demonstrating durable complete remissions in heavily pretreated patients...
November 14, 2018: Hematological Oncology
Keisuke Kawamoto, Takaharu Suzuki, Takuya Kasami, Maiko Kiryu, Hirohito Sone, Hiroaki Miyoshi, Koichi Ohshima, Jun Takizawa
No abstract text is available yet for this article.
November 5, 2018: Hematological Oncology
Renata Dos Santos Almeida, Matheus Costa E Silva, Luiz Lehmann Coutinho, Renan Garcia Gomes, Francisco Pedrosa, Juliana Doblas Massaro, Eduardo Antônio Donadi, Norma Lucena-Silva
MicroRNAs (miRNAs) play a critical role on biological and cellular processes, the search for functional markers may be of importance for differential diagnosis, prognosis and development of new therapeutic regimens. In this context, we evaluated the bone marrow miRNA profile of Brazilian children exhibiting T or B cell acute lymphoblastic leukemia (T-ALL or B-ALL), using massive parallel sequencing, using the HiSeq 2500 platform (Illumina). The differential expression analysis was conducted considering a leave-one-out approach and FDR ≤ 0...
November 4, 2018: Hematological Oncology
Takaaki Konuma, Yoshimitsu Shimomura, Yukiyasu Ozawa, Yasunori Ueda, Naoyuki Uchida, Makoto Onizuka, Megumi Akiyama, Takehiko Mori, Hirohisa Nakamae, Yuju Ohno, Souichi Shiratori, Yasushi Onishi, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ken Ishiyama
To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT...
October 29, 2018: Hematological Oncology
Carrie A Thompson, Kathleen J Yost, Matthew J Maurer, Cristine Allmer, Umar Farooq, Thomas M Habermann, David J Inwards, William R Macon, Brian K Link, Allison C Rosenthal, James R Cerhan
Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overall survival (OS). QOL was measured with the Functional Assessment of Cancer Treatment-General (FACT-G), which measures 4 domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self-Assessment (LASA) measuring overall QOL; and a spiritual WB LASA...
December 2018: Hematological Oncology
Alina Klein, Aaron Polliack, Anat Gafter-Gvili
Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin lymphoma (HL) and non-HL than the general population. Non-Hodgkin lymphoma is more common than HL in these patients, and diffuse large B cell lymphoma is the most frequent subtype observed. Although the clinical course of lymphoma in RA is often aggressive, the prognosis in these cases is similar to that of lymphoma in the general population. In this review, we summarize data derived from both retrospective and prospective studies, regarding incidence, pathogenesis, and outcome of lymphomas in RA patients and outline the possible mechanisms and hypotheses linking these 2 disorders...
December 2018: Hematological Oncology
Derek T Cawley, Joseph Butler, Adam Benton, Farhaan Altaf, Kia Rezajooi, Charalampia Kyriakou, Susanne Selvadurai, Sean Molloy
Discuss the relevant literature on surgical and non-surgical treatments for multiple myeloma (MM) and their complementary effects on overall treatment. Existing surgical algorithms designed for neoplasia of the spine may not suit the management of spinal myeloma. Less than a fifth of metastatic, including myelomatous lesions occur in the cervical spine but have a poorer prognosis and surgery in this area carries a higher morbidity. With the advances of chemotherapy, early access to radiotherapy, early orthosis management and high definition imaging including CT and MRI, surgical indications in MM have changed...
October 17, 2018: Hematological Oncology
Domenico Albano, Giovanni Bosio, Luca Camoni, Mirko Farina, Alessandro Re, Alessandra Tucci, Raffaele Giubbini, Francesco Bertagna
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent lymphoma with good prognosis and variable fluorine-18 fluorodeoxyglucose (18 F-FDG) avidity. Many possible prognostic factors have been investigated with controversial results, but the possible prognostic role of 18 F-FDG positron emission tomography/computed tomography (PET/CT) remains unclear. Our aim was to evaluate the prognostic impact of qualitative and semiquantitative baseline PET/CT parameters on outcome of MALT lymphoma. We retrospectively enrolled 161 patients with histologically confirmed MALT lymphoma who underwent 18 F-FDG PET/CT before any treatment...
October 9, 2018: Hematological Oncology
Priscilla Brito da Silva, Juliana Monte Real, Ludmila Rodrigues Pinto Ferreira, Gustavo H Esteves, Fabio do Nascimento Brito, Otavio C G Baiocchi
No abstract text is available yet for this article.
October 2018: Hematological Oncology
Shuhong Shen, Jiaoyang Cai, Jing Chen, Huiliang Xue, Ci Pan, Yijin Gao, Yanjing Tang, Jianmin Wang, Benshang Li, Xiang Wang, Jing Chen, Longjun Gu, Jingyan Tang
Long-term follow-up data for childhood acute lymphoblastic leukemia (ALL) are scarce in China because of lacking population-based and hospitalized registry system. This retrospective study, conducted at Shanghai's Children's Medical Center in China (SCMC), aimed to investigate the long-term results of childhood ALL and to identify prognostic factors. The Pediatric Oncology Network Database, designed by St. Jude Children's Research Hospital, USA, were used to collect data for the enrolled patients starting in 2005...
October 2018: Hematological Oncology
Sotirios G Papageorgiou, Christos K Kontos, Ioannis Kotsianidis, Diamantina Vasilatou, Argyris Symeonidis, Athanasios Galanopoulos, Anthi Bouchla, Eleftheria Hatzimichael, Panagiotis Repousis, Panagiotis Zikos, Nora-Athina Viniou, Elias Poulakidas, Theodoros P Vassilakopoulos, Panagiotis Diamantopoulos, Marios A Diamantopoulos, Despoina Mparmparousi, Eleni Bouronikou, Helen Papadaki, Panayiotis Panayiotidis, Vasiliki Pappa
The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of patients achieving stable disease (SD) is unclear. This retrospective study of the Hellenic MDS Study Group included 353 intermediate-2 or high IPSS risk patients treated with 5-AZA. Forty-four out of 86 (51.6%) patients achieving SD and continuing treatment with 5-AZA showed a lower risk of transformation of MDS to acute myeloid leukemia (AML) and increased overall survival (OS), compared to SD patients who discontinued the treatment (estimated median AML-free survival = 38 months, 95% CI = 10...
October 2018: Hematological Oncology
Ayako Kamiunten, Masaaki Sekine, Takuro Kameda, Keiichi Akizuki, Yuki Tahira, Kotaro Shide, Haruko Shimoda, Koji Kato, Tomonori Hidaka, Yoko Kubuki, Kazuya Shimoda
Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and four factors, namely, age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period...
October 2018: Hematological Oncology
Sarah Farag, Barbara Jeker, Ulrike Bacher, Behrouz Mansouri Taleghani, Beatrice U Mueller, Urban Novak, Thomas Pabst
Consolidation in myeloma patients with high-dose melphalan chemotherapy (Mel HDCT) and autologous transplantation (ASCT) is standard of care since more than 2 decades. However, definite cure remains exceptional despite intensive treatment, and improving effectiveness of HDCT remains an unmet clinical need. Combining intensified bendamustine with melphalan may represent an option. We analyzed safety and efficacy of combining dose-intensified bendamustine (200 mg/m2 on days -4/-3) with high-dose melphalan (100 mg/m2 on days -2/-1) before a second (tandem) ASCT in adverse risk myeloma patients after Mel HDCT/ASCT1...
October 2018: Hematological Oncology
Srdan Verstovsek, Swamy Yeleswaram, Kevin Hou, Xuejun Chen, Sue Erickson-Viitanen
Ruxolitinib is the first Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis, where its efficacy is often associated with cytopenia. It is possible that the severity of cytopenia is in part driven by Cmax . A once-daily sustained-release (SR) formulation of ruxolitinib was therefore developed to decrease the Cmax /Cmin ratio relative to twice-daily immediate-release (IR) ruxolitinib. An SR formulation was identified based on pharmacokinetic evaluation in a phase 1 study in healthy adults (N = 9)...
October 2018: Hematological Oncology
Stefanie Aeppli, Christoph Driessen, Lukas Graf, Felicitas Hitz
No abstract text is available yet for this article.
October 2018: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"